Aprea Therapeutics, Inc. (APRE) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Aprea Therapeutics, Inc. (APRE) Healthcare & Pipeline Overview

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical firm specializing in cancer therapeutics targeting DNA damage response pathways. Their primary focus is ATRN-119, an oral ATR inhibitor currently in Phase 1/2a trials for advanced solid tumors, positioning them within the competitive biotechnology sector.

What Is the Investment Thesis for APRE?

Aprea Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on DNA damage response pathways offers potential for innovative cancer treatments. The primary value driver is the successful development and commercialization of ATRN-119, currently in Phase 1/2a trials. Positive clinical trial results could significantly increase the company's valuation. Key growth catalysts include advancing ATRN-119 through clinical trials and expanding the product pipeline with ATRN-Backup, ATRN-W1051, and ATRN-DDRi. However, the company faces significant risks, including clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. With a negative profit margin of -4409.2% and negative free cash flow, Aprea's financial stability depends on securing additional funding or partnerships. The company's small size and limited resources also pose challenges to its ability to compete effectively.

Based on FMP financials and quantitative analysis

APRE Key Highlights

Lead product candidate ATRN-119 is in Phase 1/2a clinical trial targeting advanced solid tumors.

• Gross margin of 92.4% indicates strong potential profitability if products reach commercialization.
• Market capitalization of $9.58M reflects the company's early stage and associated risks.
• Negative profit margin of -4409.2% highlights the significant R&D expenses and lack of revenue generation.
• Beta of 1.55 suggests higher volatility compared to the overall market.

Who Are APRE's Competitors?

APRE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are APRE's Key Strengths?

Novel DDR-targeted therapies.

• Lead product candidate in clinical trials.
• Experienced management team.
• Strong intellectual property portfolio.

What Are APRE's Weaknesses?

Limited financial resources.

• Small team size.
• Dependence on clinical trial outcomes.
• Lack of commercialized products.

What Could Drive APRE Stock Higher?

Phase 1/2a clinical trial data readout for ATRN-119.

• Initiation of clinical trials for ATRN-Backup.
• Advancement of ATRN-W1051 and ATRN-DDRi through preclinical studies.
• Potential strategic partnerships or collaborations.

What Are the Key Risks for APRE?

Financial-distress signal — its Altman Z-Score of -9.59 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-59.5%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for ATRN-119 or other product candidates.
• Regulatory delays or rejection of marketing applications.
• Competition from established pharmaceutical companies.
• Funding constraints and dependence on external financing.
• Intellectual property challenges or patent infringement.

What Are the Growth Opportunities for APRE?

• Advancement of ATRN-119 through clinical trials: The successful completion of Phase 1/2a trials and subsequent progression to Phase 2 and Phase 3 trials for ATRN-119 represents a significant growth opportunity. Positive data could lead to accelerated regulatory approval and eventual commercialization, addressing a substantial market in advanced solid tumors. The timeline for this growth opportunity is estimated at 3-5 years, contingent on trial outcomes and regulatory processes.
• Expansion of the product pipeline: Developing and advancing ATRN-Backup, ATRN-W1051, and ATRN-DDRi into clinical trials offers additional growth potential. Each of these compounds targets different aspects of DNA damage response, potentially expanding Aprea's therapeutic reach and market opportunities. This expansion could take 2-4 years per compound, depending on preclinical and early clinical results.
• Strategic partnerships and collaborations: Forming partnerships with larger pharmaceutical companies or research institutions could provide Aprea with access to additional funding, expertise, and resources. Such collaborations could accelerate the development and commercialization of its product candidates, enhancing its competitive position and market penetration. This opportunity could materialize within the next 1-2 years.
• Targeting specific cancer subtypes: Focusing on specific cancer subtypes with high unmet needs could improve the chances of clinical trial success and regulatory approval. By tailoring its therapies to specific patient populations, Aprea can potentially achieve better outcomes and gain a competitive advantage. This targeted approach could yield results within 2-3 years.
• Exploring combination therapies: Investigating the potential of combining its DDR-targeted therapies with other cancer treatments, such as chemotherapy or immunotherapy, could enhance their efficacy and broaden their applicability. Combination therapies often show synergistic effects, leading to improved patient outcomes. This exploration could start within the next year and yield results in 2-3 years.

What Are APRE's Competitive Advantages?

• Proprietary DDR-targeted therapies.
• Intellectual property protection (patents).
• Clinical trial data and regulatory expertise.
• First-mover advantage in specific DDR pathways.

What Does APRE Do?

Aprea Therapeutics, Inc., based in Boston, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to the discovery and commercialization of innovative cancer treatments. The company focuses on developing therapies that target DNA damage response (DDR) pathways, a critical area in cancer research. Their lead product candidate, ATRN-119, is an oral ATR (Ataxia-Telangiectasia and Rad3-related protein) inhibitor. ATRN-119 is currently undergoing a Phase 1/2a clinical trial to evaluate its safety and efficacy in patients with advanced solid tumors. The trial aims to determine the optimal dosage and assess the drug's potential to inhibit tumor growth. Aprea's pipeline also includes ATRN-Backup, another ATR inhibitor, ATRN-W1051, designed to exhibit anti-tumor activity, and ATRN-DDRi, a compound targeting DDR pathways. These programs reflect Aprea's commitment to expanding its portfolio of novel cancer therapeutics. Founded with the vision of addressing unmet needs in cancer treatment, Aprea Therapeutics operates with a lean team of 8 employees, allowing for focused and agile drug development. The company's strategy involves rigorous preclinical and clinical evaluation of its drug candidates to ensure their potential for improving patient outcomes. Aprea Therapeutics aims to establish itself as a key player in the field of DDR-targeted cancer therapies.

What Products and Services Does APRE Offer?

• Develop novel cancer therapeutics.
• Target DNA damage response pathways.
• Focus on oral ATR inhibitors.
• Conduct clinical trials for advanced solid tumors.
• Advance ATRN-119 through clinical development.
• Expand product pipeline with ATRN-Backup, ATRN-W1051, and ATRN-DDRi.
• Seek strategic partnerships for funding and expertise.

How Does APRE Make Money?

• Develop and commercialize cancer therapeutics.
• Out-license or partner with larger pharmaceutical companies for commercialization.
• Generate revenue through product sales upon regulatory approval.
• Secure funding through venture capital, grants, and partnerships.

What Industry Does APRE Operate In?

Aprea Therapeutics operates within the competitive biotechnology industry, which is characterized by high R&D spending, lengthy development timelines, and stringent regulatory requirements. The market for cancer therapeutics is substantial and growing, driven by an aging population and increasing cancer incidence rates. Companies like Aprea focus on specific therapeutic targets, such as DNA damage response pathways, to differentiate themselves. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying for market share in this lucrative sector. Success depends on innovation, clinical trial outcomes, and regulatory approvals.

Who Are APRE's Key Customers?

• Patients with advanced solid tumors.
• Oncologists and medical professionals.
• Hospitals and cancer treatment centers.
• Pharmaceutical companies (potential partners).

Company Profile

Aprea Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Oren Gilad. APRE has traded publicly since 2019.

Return on equity for Aprea Therapeutics, Inc. stands at -59.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -24.8%, showing how much profit it generates from its asset base. A current ratio of 8.92 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -174.2%, the inverse of the P/E and a quick read on earnings relative to price.

APRE Valuation & Market Position

With a $9.58M market cap, Aprea Therapeutics, Inc. sits in the micro-cap segment of the market. Relative to its peer group, APRE's quantitative score of 32/100 is below the peer average of 78/100.

Quarterly Financial Performance: Aprea Therapeutics, Inc.

Revenue for Aprea Therapeutics, Inc. came in at $0 during Q2 FY2026. The company recorded a net loss of $3.6M, with diluted EPS of $-0.07. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, APRE averaged $-0.32 in diluted EPS.

Aprea Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.59 places it in the distress zone, a signal of elevated financial risk.

Aprea Therapeutics, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 21.6% below estimates on average.

Over the past six months, Aprea Therapeutics, Inc. insiders filed 20 SEC Form 4 transactions — 0 sales and 20 purchases. On net that is roughly 435K shares acquired (about $179K) — insiders putting money in tends to read as conviction.

APRE Financials

APRE Latest News

APRE Analyst Consensus

APRE MoonshotScore

Common Questions About APRE (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources